Drug Trial Radar · NCT03890302
Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A
Last checked: Nov 19, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Mar 14, 2019
Primary completion
May 27, 2020
Study completion May 27, 2020
Sponsor
- Lead sponsor
- Fountain Biopharma Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Oneness Biotech Co., Ltd.
- First posted
- Mar 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a major role in chronic inflammation that is typical in RA. This study investigates the drug FB704A, which is believed to lower the inflammation caused by IL-6. This study will be in 2 sequential parts: a single increasing dose part (Part 1) and a multiple-increasing dose part (Part 2). Subjects will receive either active or placebo drug by IV infusion. Subjects in both parts will have a short stay in the clinic at the start of the study, then will return for outpatient visits.
Conditions
- Rheumatoid Arthritis
Interventions
FB704ADrug
Administered by IV infusion
PlaceboDrug
Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) (Part 1)Time frame: Up to Day 57
- Incidence of Adverse Events (AEs) (Part 2)Time frame: Up to Day 99
- Number of participants with clinical laboratory abnormalities (Part 1)Time frame: Up to Day 57
- Number of participants with clinical laboratory abnormalities (Part 1)Time frame: Up to Day 99
- Number of participants with physical examination abnormalities (Part 1)Time frame: Up to Day 57
- Number of participants with physical examination abnormalities (Part 2)Time frame: Up to Day 99
- Number of participants with dose limiting toxicities (DLT) (Part 1)Time frame: Up to Day 57
- Number of participants with dose limiting toxicities (DLT) (Part 2)Time frame: Up to Day 99
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences Clinical Kansas, Inc.
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.